Performance of a web-based application measuring spot quality in dried blood spot sampling.
dried blood spots
specimen quality evaluation
therapeutic drug monitoring
web application
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
26 Nov 2019
26 Nov 2019
Historique:
received:
26
04
2019
accepted:
15
07
2019
pubmed:
3
8
2019
medline:
18
9
2020
entrez:
3
8
2019
Statut:
ppublish
Résumé
Background The dried blood spot (DBS) method allows patients and researchers to collect blood on a sampling card using a skin-prick. An important issue in the application of DBSs is that samples for therapeutic drug monitoring are frequently rejected because of poor spot quality, leading to delayed monitoring or missing data. We describe the development and performance of a web-based application (app), accessible on smartphones, tablets or desktops, capable of assessing DBS quality at the time of sampling by means of analyzing a picture of the DBS. Methods The performance of the app was compared to the judgment of experienced laboratory technicians for samples obtained in a trained and untrained setting. A robustness- and user test were performed. Results In a trained setting the app yielded an adequate decision in 90.0% of the cases with 4.1% false negatives (insufficient quality DBSs incorrectly not rejected) and 5.9% false positives (sufficient quality DBSs incorrectly rejected). In an untrained setting this was 87.4% with 5.5% false negatives and 7.1% false positives. A patient user test resulted in a system usability score of 74 out of 100 with a median time of 1 min and 45 s to use the app. Robustness testing showed a repeatability of 84%. Using the app in a trained and untrained setting improves the amount of sufficient quality samples from 80% to 95.9% and 42.2% to 87.9%, respectively. Conclusions The app can be used in trained and untrained setting to decrease the amount of insufficient quality DBS samples.
Identifiants
pubmed: 31373896
doi: 10.1515/cclm-2019-0437
pii: cclm-2019-0437
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1846-1853Commentaires et corrections
Type : CommentIn
Références
Hofman S, Bolhuis MS, Koster RA, Akkerman OW, van Assen S, Stove C, et al. Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. Bioanalysis 2015;7:481–95.
Veenhof H, Koster RA, Alffenaar JW, Berger SP, Bakker SJ, TouwDJ. Clinical validation of simultaneous analysis of tacrolimus, cyclosporine A and creatinine in dried blood spots in kidney transplant patients. Transplantation 2017;101:1727.
Vu D, Alffenaar J, Edelbroek P, Brouwers J, Uges D. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des 2011;17:2931–9.
Eick G, Urlacher SS, McDade TW, Kowal P, Snodgrass JJ. Validation of an optimized ELISA for quantitative assessment of Epstein-Barr virus antibodies from dried blood spots. Biodemogr Soc Biol 2016;62:222–33.
Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 2009;31:327–36.
Hoogtanders K, van der Heijden J, Christiaans M, Edelbroek P, van Hooff JP, Stolk LM. Therapeutic drug monitoring of tacrolimus with the dried blood spot method. J Pharm Biomed Anal 2007;44:658–64.
Enderle Y, Foerster K, Burhenne J. Clinical feasibility of dried blood spots: analytics, validation, and applications. J Pharm Biomed Anal 2016;130:231–43.
CLSI. Blood collection on Filter Paper for Newborn Screening Programs; Approved Standard – Sixth Edition. CLSI Document NBS01-A6. Wayne, PA: Clinical and Laboratory Standards Institute 2013;NBS01-A6.
Panchal T, Spooner N, Barfield M. Ensuring the collection of high-quality dried blood spot samples across multisite clinical studies. Bioanalysis 2017;9:209–13.
Al-Uzri AA, Freeman KA, Wade J, Clark K, Bleyle LA, Munar M, et al. Longitudinal study on the use of dried blood spots for home monitoring in children after kidney transplantation. Pediatr Transplant JID – 9802574, OTO – NOTNLM 0621, LID – doi:10.1111/petr.12983.
Zuur M, Veenhof H, Aleksa A, van ’t Boveneind-Vrubleuskaya N, Darmawan E, Hasnain G, et al. Quality assessment of dried blood spots from tuberculosis patients from four countries. Ther Drug Monit 2019, doi: 10.1097/FTD.0000000000000659.
Zakaria R, Allen KJ, Koplin JJ, Roche P, Greaves RF. Advantages and challenges of Dried Blood Spot analysis by mass spectrometry across the total testing process. EJIFCC JID – 101092742, PMC – PMC5282914, OTO – NOTNLM 0202.
World Health Organization. Participant Manual Module 14 Blood Collection and Handling – Dried Blood Spot (DBS). 2005; Module 14: EQA (December).
Vu DH, Bolhuis MS, Koster RA, Greijdanus B, de Lange WC, van Altena R, et al. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2012;56:5758–63.
Dantonio PD, Stevens G, Hagar A, Ludvigson D, Green D, Hannon H, et al. Comparative evaluation of newborn bloodspot specimen cards by experienced laboratory personnel and by an optical scanning instrument. Mol Genet Metab 2014;113:62–6.
Abdi A, Emming G, Koster R. University Medical Centre Groningen – DBS Instruction 2017. Available at: www.driedbloodspot.umcg.nl. Accessed: December 19, 2017.
Validation of analytical procedures: text and methodology Q2 (R1). Geneva, Switzerland: International Conference on Harmonization; 2005.
International Organization for Standardization. ISO 9241-11: Ergonomic Requirements for Office Work with Visual Display Terminals (VDTs): Part 11: Guidance on Usability. ISO 9241 1998: Part 11.
Georgsson M, Staggers N. An evaluation of patients’ experienced usability of a diabetes mHealth system using a multi-method approach. J Biomed Inform 2016;59:115–29.
Georgsson M, Staggers N. Quantifying usability: an evaluation of a diabetes mHealth system on effectiveness, efficiency, and satisfaction metrics with associated user characteristics. J Am Med Informatics Assoc 2015;23:5–11.
Brooke J. SUS: a quick and dirty usability scale. In: Jordan PW, Weerdmeester B, Thomas A, Mclelland IL, editors. Usability evaluation in industry 1996.
Brooke J. SUS: a retrospective. J Usability Stud 2013;8:29–40.
Virzi RA. Refining the test phase of usability evaluation: how many subjects is enough? Hum Factors 1992;34:457–68.
Denniff P, Spooner N. Effect of storage conditions on the weight and appearance of dried blood spot samples on various cellulose-based substrates. Bioanalysis 2010;2:1817–22.
Koster RA, Botma R, Greijdanus B, Uges DR, Kosterink JG, TouwDJ, et al. The performance of five different dried blood spot cards for the analysis of six immunosuppressants. Bioanalysis 2015;7:1225–35.
International Organization for Standardization. Medical laboratories – requirements for quality and competence. ISO 15189 2012:5.4.6e.
Study Group 1 of the Global Harmonization Task Force. Definition of the Terms ‘Medical Device’ and ‘In Vitro Diagnostic (IVD) Medical Device’. 2012;GHTF/SG1/N071.